Arranon Solution For Injection 5Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Arranon: Solution for injection (5mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

NELARABINE (nel AR a been) is a chemotherapy drug. It interferes with the growth of cancer cells. It is used to treat T-cell lymphoblastic leukemias and lymphomas.

In-Depth Information

Arranon 250mg/50ml Solution for Injection

NDC: 000074401
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
T-cell Leukemia/lymphoma

Sometimes used for but not FDA approved for the following conditions:
Chronic Lymphocytic Leukemia (CLL)

Storage Information
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Arranon 250mg/50ml Solution for Injection

Reported Side Effects for Arranon 250mg/50ml Solution for Injection

Paresthesias Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Nerve Pain Incidence:
<6.0%*
Severity: SEVERE
Onset: DELAYED
Collapsed Lung Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Vomiting Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Breakdown Of Muscle Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Drowsiness Incidence:
<2.0%*
Severity: SEVERE
Onset: EARLY
Guillain-Barre Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Weakness Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Unable To Speak Incidence:
1.0%*
Severity: MODERATE
Onset: DELAYED
Muscle Pain Incidence:
1.0%*
Severity: SEVERE
Onset: EARLY
Nerve Pain Incidence:
1.0%*
Severity: MODERATE
Onset: DELAYED
Fast Eye Movements Incidence:
1.0%*
Severity: MODERATE
Onset: DELAYED
Convulsions Incidence:
1.0-6.0%*
Severity: SEVERE
Onset: DELAYED
Sinus Infection Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Mouth Ulcers Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Rapid Heart Rate Incidence:
1.0%*
Severity: SEVERE
Onset: RAPID
Stomach Pain Incidence:
1.0%*
Severity: SEVERE
Onset: EARLY
Brain Dysfunction Incidence:
1.0%*
Severity: MODERATE
Onset: DELAYED
Increased Blood Sugar Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Bleeding In The Brain Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Joint Pain Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Coma Incidence:
1.0%*
Severity: SEVERE
Onset: EARLY
Constipation Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Paresis Incidence:
1.0%*
Severity: MODERATE
Onset: DELAYED
Muscle Paralysis Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Depression Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Loose Stools Incidence:
1.0%*
Severity: SEVERE
Onset: EARLY
Brain Deterioration Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Tiredness Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Decreased Reflexes Incidence:
1.0%*
Severity: MILD
Onset: DELAYED
Excessive Mucle Tone Incidence:
1.0%*
Severity: MODERATE
Onset: DELAYED
Headache Incidence:
1.0-6.0%*
Severity: SEVERE
Onset: EARLY
Swelling Of The Brain Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Dysarthria Incidence:
1.0%*
Severity: MODERATE
Onset: DELAYED
Incoordination Incidence:
1.0-2.0%*
Severity: SEVERE
Onset: DELAYED
Hypoesthesia Incidence:
2.0-4.0%*
Severity: SEVERE
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
2.0-4.0%*
Severity: SEVERE
Onset: DELAYED
Confusion Incidence:
2.0%*
Severity: SEVERE
Onset: EARLY
Red Spotted Rash Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Low Calcium Levels Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Low Magnesium Levels Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Low Blood Pressure Incidence:
2.0%*
Severity: SEVERE
Onset: RAPID
Loss Of Memory Incidence:
3.0%*
Severity: MODERATE
Onset: DELAYED
Infection Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Metallic Taste Incidence:
3.0%*
Severity: MILD
Onset: EARLY
Shaking Incidence:
4.0-5.0%*
Severity: MILD
Onset: EARLY
Dehydration Incidence:
4.0%*
Severity: SEVERE
Onset: DELAYED
Blurred Vision Incidence:
4.0%*
Severity: MODERATE
Onset: EARLY
Low Blood Sugar Incidence:
4.0%*
Severity: SEVERE
Onset: EARLY
Weakness Incidence:
5.0%*
Severity: SEVERE
Onset: EARLY
Chest Pain Incidence:
5.0%*
Severity: MODERATE
Onset: EARLY
Fever Incidence:
5.0%*
Severity: SEVERE
Onset: EARLY
Wheezing Incidence:
5.0%*
Severity: MODERATE
Onset: RAPID
Low Albumin In Blood Incidence:
6.0%*
Severity: SEVERE
Onset: DELAYED
Shortness Of Breath Incidence:
6.0%*
Severity: SEVERE
Onset: EARLY
Low Potassium Levels Incidence:
6.0%*
Severity: SEVERE
Onset: DELAYED
Inability To Sleep Incidence:
7.0%*
Severity: MILD
Onset: EARLY
Nose Bleed Incidence:
8.0%*
Severity: MILD
Onset: DELAYED
Chills Incidence:
8.0%*
Severity: MILD
Onset: RAPID
Back Pain Incidence:
8.0%*
Severity: MILD
Onset: DELAYED
High Bilirubin Level Incidence:
9.0%*
Severity: SEVERE
Onset: DELAYED
Decreased Appetite Incidence:
9.0%*
Severity: MILD
Onset: DELAYED
Fluid Around The Lungs Incidence:
10.0%*
Severity: SEVERE
Onset: DELAYED
Swelling Incidence:
11.0%*
Severity: MODERATE
Onset: DELAYED
Tired Incidence:
12.0%*
Severity: SEVERE
Onset: EARLY
Fluid Retention Incidence:
15.0%*
Severity: MODERATE
Onset: DELAYED
Lightheadedness Incidence:
21.0%*
Severity: MILD
Onset: EARLY
Low White Blood Cell Counts Incidence:
21.0%*
Severity: SEVERE
Onset: DELAYED
Cough Incidence:
25.0%*
Severity: MILD
Onset: DELAYED
Anemia Incidence:
34.0-55.0%*
Severity: SEVERE
Onset: DELAYED
Upset Stomach Incidence:
41.0%*
Severity: MILD
Onset: EARLY
Low Platelet Count Incidence:
59.0%*
Severity: SEVERE
Onset: DELAYED
Low White Blood Cells Incidence:
63.0-79.0%*
Severity: SEVERE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Arranon

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5